GleamWall
中文EN

RNAC Cartesian Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1453687 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-6.0%
TTM net income YoY-165.7%
TTM EPS YoY-259.4%
Revenue 3-yr CAGR-69.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-15,540.9%
Net margin-12,435.2%
FCF margin-8,770.0%
EBITDA margin-15,267.7%

Returns

ROE—
ROA-38.2%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets144.3%
Debt / equity—
Current ratio8.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.70x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue120.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$2.80M$38.91M
R&D expense$58.03M$45.10M
SG&A expense$31.47M$30.13M
Operating income-$143.41M-$43.90M
Interest expense—$0
Pretax income-$139.50M-$77.14M
Income tax-$9.19M$287,000
Net income-$130.30M-$77.42M
EBITDA-$141.00M-$42.70M
EPS (basic)-5.02-4.48
EPS (diluted)-5.02-4.49
Weighted avg. shares (diluted)25.97M17.36M
Balance sheet
Cash & equivalents$125.14M$214.28M
Receivables$1.11M$872,000
Current assets$129.28M$216.63M
PP&E, net$12.19M$9.91M
Goodwill$48.16M$48.16M
Total assets$296.41M$435.02M
Current liabilities$14.94M$22.98M
Long-term debt$0—
Total debt$0—
Total liabilities$422.65M$441.82M
Shareholders' equity-$126.24M-$6.80M
Net debt-$125.14M—
Shares outstanding26.01M25.77M
Cash flow statement
Operating cash flow-$73.94M-$23.67M
Capital expenditure$5.45M$9.09M
Free cash flow-$79.39M-$32.77M
Investing cash flow-$5.45M-$8.74M
Financing cash flow-$8.05M$168.43M
Depreciation & amortization$2.40M$1.20M
Stock-based compensation$10.52M$6.58M

Free plan shows the latest 2 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.